I doubt that.. Their strategy with INDs, Andrews, etc and the FDA is U.S. based and they already have that patent.
More likely would be contingent on new leadership and FDA status as being able to bypass some or all of the IND process makes a big difference in what is needed to push the technology forward..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.